SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 29, 2012
Interleukin Genetics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
(e) On November 29, 2012, Interleukin Genetics, Inc. (the “Company”) entered into the Second Amendment (the “Amendment”) to the employment agreement, dated November 12, 2008 (the “Agreement”), with its Chief Executive Officer, Chief Scientific Officer and President, Kenneth S. Kornman. The Amendment extends the term of the Agreement through November 30, 2015. The terms of the Agreement were set forth in “Part II - Item 5. Other Information” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, as filed with the Securities and Exchange Commission on November 13, 2008 (File No. 001-32715), and are incorporated herein by reference. A copy of the Amendment is filed as Exhibit 10.1 hereto and is incorporated by reference herein.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.